NIA-AA阿尔茨海默病框架:各阶段的临床特征描述
该研究基于Mayo Clinic老龄化研究队列,对243名淀粉样蛋白异常且无痴呆的参与者,按NIA-AA研究框架的6阶段临床进展进行横断面分类和15个月纵向稳定性评估。结果显示各阶段频率随年龄变化显著,且阶段归属随定义参数波动,尤其阶段2短期稳定性差,提示该框架用于临床试验前可能需修订。
要点
- 淀粉样蛋白异常人群的阶段分布随年龄变化:50岁时66-90%为阶段1,80岁时仅24-36%为阶段1。
- 阶段2中44-59%仅因客观认知变化(ΔOBJ)异常而归入,11-21%仅有主观认知下降(SCD)。
- 阶段2短期稳定性差:38-63%保持稳定,4-13%恶化,24-41%改善至阶段1。
核心结论
- NIA-AA框架各阶段频率随年龄变化,且阶段归属随定义参数波动,用于临床试验前可能需修订。
研究设计与样本
- 基于Mayo Clinic老龄化研究(明尼苏达州奥姆斯特德县人群队列)的纵向研究,纳入243名淀粉样蛋白异常且无痴呆、完成连续3次临床访视的参与者。
主要发现
- 在243名淀粉样蛋白异常参与者中,50岁时66-90%为阶段1;80岁时24-36%为阶段1、32-47%为阶段2、18-27%为阶段3、1-3%为阶段4-6、3-9%无法确定。
- 阶段2参与者中44-59%仅因ΔOBJ异常归入,11-21%仅有SCD,9-13%仅有ΔNBS。
- 15个月随访中阶段2稳定性因阶段和OBJ截断值而异:38-63%保持稳定,4-13%恶化,24-41%改善至阶段1。
关键数值与推荐
- 横断面分类指标包括客观认知损害(OBJ)和功能(FXN);变化指标包括主观认知损害(SCD)、客观认知变化(ΔOBJ)和新发神经行为症状(ΔNBS)。
- 阶段频率使用不同截断点计算,并评估15个月内的稳定性。
临床怎么用
- 临床使用NIA-AA框架分期时需注意年龄对阶段分布的影响,并警惕阶段2归属的不稳定性。
- 阶段2的判定应综合ΔOBJ、SCD和ΔNBS,避免仅凭单一指标分类。
局限性
- 研究基于特定人群队列,结果外推需谨慎。
- 阶段定义参数(如OBJ截断点)不同导致阶段归属波动,框架本身可能需修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To operationalize the National Institute on Aging - Alzheimer's Association (NIA-AA) Research Framework for Alzheimer's Disease 6-stage continuum of clinical progression for persons with abnormal amyloid. METHODS: The Mayo Clinic Study of Aging is a population-based longitudinal study of aging and cognitive impairment in Olmsted County, Minnesota. We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross-sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS). We calculated frequencies of the stages using different cutoff points and assessed stability of the stages over 15 months. RESULTS: Among 243 abnormal amyloid participants, the frequencies of the stages varied with age: 66 to 90% were classified as stage 1 at age 50 but at age 80, 24 to 36% were stage 1, 32 to 47% were stage 2, 18 to 27% were stage 3, 1 to 3% were stage 4 to 6, and 3 to 9% were indeterminate. Most stage 2 participants were classified as stage 2 because of abnormal ΔOBJ only (44-59%), whereas 11 to 21% had SCD only, and 9 to 13% had ΔNBS only. Short-term stability varied by stage and OBJ cutoff points but the most notable changes were seen in stage 2 with 38 to 63% remaining stable, 4 to 13% worsening, and 24 to 41% improving (moving to stage 1). INTERPRETATION: The frequency of the stages varied by age and the precise membership fluctuated by the parameters used to define the stages. The staging framework may require revisions before it can be adopted for clinical trials. ANN NEUROL 2021;89:1145-1156.
引用
- Petersen RC, Wiste HJ, Weigand SD, et al. NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages. Ann Neurol. 2021. PMID: 33772866. doi:10.1002/ana.26071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。